189 related articles for article (PubMed ID: 15956279)
1. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Schneider P; Nollau P; Horstmann M; Beverloo HB; van der Voort E; Valsecchi MG; de Lorenzo P; Sallan SE; Armstrong SA; Pieters R
Blood; 2005 Oct; 106(7):2484-90. PubMed ID: 15956279
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
Armstrong SA; Kung AL; Mabon ME; Silverman LB; Stam RW; Den Boer ML; Pieters R; Kersey JH; Sallan SE; Fletcher JA; Golub TR; Griffin JD; Korsmeyer SJ
Cancer Cell; 2003 Feb; 3(2):173-83. PubMed ID: 12620411
[TBL] [Abstract][Full Text] [Related]
3. FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia.
Català A; Pastor-Anglada M; Caviedes-Cárdenas L; Malatesta R; Rives S; Vega-García N; Camós M; Fernández-Calotti P
Oncotarget; 2016 Aug; 7(31):49786-49799. PubMed ID: 27391351
[TBL] [Abstract][Full Text] [Related]
4. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.
Zhu Y; He X; Lin YC; Dong H; Zhang L; Chen X; Wang Z; Shen Y; Li M; Wang H; Sun J; Nguyen LX; Zhang H; Jiang W; Yang Y; Chen J; Müschen M; Chen CW; Konopleva MY; Sun W; Jin J; Carlesso N; Marcucci G; Luo Y; Li L
Blood; 2019 Oct; 134(15):1257-1268. PubMed ID: 31395602
[TBL] [Abstract][Full Text] [Related]
5. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Taketani T; Taki T; Sugita K; Furuichi Y; Ishii E; Hanada R; Tsuchida M; Sugita K; Ida K; Hayashi Y
Blood; 2004 Feb; 103(3):1085-8. PubMed ID: 14504097
[TBL] [Abstract][Full Text] [Related]
6. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
[TBL] [Abstract][Full Text] [Related]
7. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia.
Ozeki K; Kiyoi H; Hirose Y; Iwai M; Ninomiya M; Kodera Y; Miyawaki S; Kuriyama K; Shimazaki C; Akiyama H; Nishimura M; Motoji T; Shinagawa K; Takeshita A; Ueda R; Ohno R; Emi N; Naoe T
Blood; 2004 Mar; 103(5):1901-8. PubMed ID: 14604973
[TBL] [Abstract][Full Text] [Related]
8. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
Brown P; Levis M; McIntyre E; Griesemer M; Small D
Leukemia; 2006 Aug; 20(8):1368-76. PubMed ID: 16761017
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
[TBL] [Abstract][Full Text] [Related]
11. TGFβ1 synergizes with FLT3 ligand to induce chemoresistant quiescence in acute lymphoblastic leukemia with MLL gene rearrangements.
Tamai M; Furuichi Y; Kasai S; Ando N; Harama D; Goi K; Inukai T; Kagami K; Abe M; Ichikawa H; Sugita K
Leuk Res; 2017 Oct; 61():68-76. PubMed ID: 28917156
[TBL] [Abstract][Full Text] [Related]
12. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.
Brown P; Levis M; Shurtleff S; Campana D; Downing J; Small D
Blood; 2005 Jan; 105(2):812-20. PubMed ID: 15374878
[TBL] [Abstract][Full Text] [Related]
13. D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia.
Stam RW; den Boer ML; Schneider P; Meier M; Beverloo HB; Pieters R
Haematologica; 2007 Nov; 92(11):1565-8. PubMed ID: 18024407
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia.
Chillón MC; Gómez-Casares MT; López-Jorge CE; Rodriguez-Medina C; Molines A; Sarasquete ME; Alcoceba M; Miguel JD; Bueno C; Montes R; Ramos F; Rodríguez JN; Giraldo P; Ramírez M; García-Delgado R; Fuster JL; González-Díaz M; Menendez P
Leukemia; 2012 Nov; 26(11):2360-6. PubMed ID: 22705992
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
Weisberg E; Boulton C; Kelly LM; Manley P; Fabbro D; Meyer T; Gilliland DG; Griffin JD
Cancer Cell; 2002 Jun; 1(5):433-43. PubMed ID: 12124173
[TBL] [Abstract][Full Text] [Related]
16. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Passier MM; Janka-Schaub GE; Sallan SE; Armstrong SA; Pieters R
Leukemia; 2006 Feb; 20(2):264-71. PubMed ID: 16357833
[TBL] [Abstract][Full Text] [Related]
17. Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood AML Cooperative Study Group.
Shimada A; Taki T; Tabuchi K; Taketani T; Hanada R; Tawa A; Tsuchida M; Horibe K; Tsukimoto I; Hayashi Y
Pediatr Blood Cancer; 2008 Feb; 50(2):264-9. PubMed ID: 17763464
[TBL] [Abstract][Full Text] [Related]
18. Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes.
Albouhair S; Morgado E; Lavau C
PLoS One; 2013; 8(8):e72261. PubMed ID: 23977266
[TBL] [Abstract][Full Text] [Related]
19. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
Cools J; Mentens N; Furet P; Fabbro D; Clark JJ; Griffin JD; Marynen P; Gilliland DG
Cancer Res; 2004 Sep; 64(18):6385-9. PubMed ID: 15374944
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia.
Steudel C; Wermke M; Schaich M; Schäkel U; Illmer T; Ehninger G; Thiede C
Genes Chromosomes Cancer; 2003 Jul; 37(3):237-51. PubMed ID: 12759922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
